Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion at 140% Premium

Biogen (BIIB) has finalized the acquisition of Apellis Pharmaceuticals (APLS) in a deal valued at approximately $5.6 billion to strengthen its specialized drug portfolio. The transaction represents a significant 140% premium over Apellis's market value, reflecting Biogen's aggressive push into new therapeutic areas. Through this deal, Biogen gains access to EMPAVELI, a treatment for rare kidney diseases, and the drug SYFOVRE, which has recently faced revenue challenges. Management expects the acquisition to become accretive to Biogen's non-GAAP diluted earnings per share starting in 2027. This strategic expansion aims to offset headwinds in Biogen's core business segments by integrating new therapeutic pipelines. However, the high premium and the current performance of Apellis's lead assets have created a mixed outlook among market analysts regarding the short-term impact.